Načítá se...
The PARTHENON Clinical Development Program: the Role of Ticagrelor in Patients with Atherothrombotic Disease
Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US...
Uloženo v:
| Vydáno v: | Cardiovasc Drugs Ther |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer US
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5591813/ https://ncbi.nlm.nih.gov/pubmed/28866767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10557-017-6749-7 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|